Propel Bio Management LLC Acquires Shares of 1,000,000 Inventiva S.A. Sponsored ADR $IVA

Propel Bio Management LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,000,000 shares of the company’s stock, valued at approximately $4,650,000. Inventiva accounts for approximately 4.0% of Propel Bio Management LLC’s investment portfolio, making the stock its 8th biggest position. Propel Bio Management LLC owned 0.69% of Inventiva as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Creative Planning purchased a new position in shares of Inventiva during the 2nd quarter valued at $32,000. NewEdge Advisors LLC purchased a new position in shares of Inventiva during the 3rd quarter valued at $116,000. Wealth Enhancement Advisory Services LLC lifted its position in shares of Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Inventiva during the 3rd quarter valued at $649,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Inventiva during the 4th quarter valued at $1,570,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

Shares of NASDAQ IVA opened at $4.03 on Friday. Inventiva S.A. Sponsored ADR has a 1-year low of $2.85 and a 1-year high of $7.98. The stock’s 50-day moving average is $5.25 and its 200 day moving average is $5.40.

Inventiva (NASDAQ:IVA) last released its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. Equities research analysts expect that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on IVA shares. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial began coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.